EcoDrugPlus

Solute Carrier Family 18 Member A2

Ensembl ID : ENSELUG00000013933
Gene Symbol: SLC18A2
3 Cross references
224 Possible Orthologues:

Solute Carrier Family 22 Member 6

Ensembl ID : ENSELUG00000022804
Gene Symbol: LOC105010906
3 Cross references
360 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSELUG00000015955
Gene Symbol: SLC29A1
4 Cross references
191 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSELUG00000023415
Gene Symbol: SLC29A1
3 Cross references
206 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSELUG00000019527
Gene Symbol: SLC5A2
3 Cross references
199 Possible Orthologues:

Solute Carrier Family 6 Member 1

Ensembl ID : ENSELUG00000015754
Gene Symbol: SLC6A1
3 Cross references
207 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSELUG00000005686
Gene Symbol: SLC6A2
3 Cross references
204 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSELUG00000002666
Gene Symbol: SLC6A3
3 Cross references
167 Possible Orthologues:

Solute Carrier Family 6 Member 4

Ensembl ID : ENSELUG00000009919
Gene Symbol: SLC6A4
3 Cross references
203 Possible Orthologues:

Solute Carrier Family 6 Member 9

Ensembl ID : ENSELUG00000000439
Gene Symbol: SLC6A9
3 Cross references
207 Possible Orthologues:

Solute Carrier Family 9 Member A3

Ensembl ID : ENSELUG00000022644
Gene Symbol: SLC9A3
3 Cross references
238 Possible Orthologues:

Somatostatin Receptor 1

Ensembl ID : ENSELUG00000003269
Gene Symbol: SSTR1
3 Cross references
160 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).